Iron containing products include- Ferrous Sulphate, Ferrous gluconate,Ferrous fumerate, Polysaccharide -Iron Complex, Iron with Vitamin C

Refer - Ferrous Fumarate

Iron interacts with certain chelates of medical importance; bisulphonates, antacids, and tertacycline antimicrobials Food markedly affects bioavailability of iron in gastrointestinal lumen. Ascorbic acid enhances the absorption of iron.

Iron containing products include- Ferrous Sulphate, Ferrous gluconate,Ferrous fumerate, Polysaccharide -Iron Complex, Iron with Vitamin C

Refer - Ferrous Fumarate

Iron deficiency anemia

Occasionally gastrointestinal irritations such as feeling of repletion pressure in the epigastric region, nausea, constipation or diarrhea can occur.

Hypersensitivity or intolerance to iron and overloading of iron in the body. Primary (idiopathic) or secondary iron storage disease. Anemia associated with ineffective erythropoiesis, bone marrow hypoplasia, sideroblastic change. Intestinal disease. Anemia not caused by iron deficiency Prophyria cutanea tardia.

Special precautions: As with all iron preparations, a dark colouration of the stool may occur which is without clinical significance.

Control studies in pregnant women after the first trimester have not shown any undesirable effects on mother and neonates. It is not known how much iron from the complex is passed on into mothers milk.

The administration is unlikely to cause undesirable effects to the nursed child. Should not be simultaneously administered with tetracycline which may result in diminished adsorption of both ingredients. Absorption of iron is decreased in the presence of antacids or when taken with tea. Iron salts appear to reduce the effects of of penicillanse.

Iron deficiency anemias caps- 1 cap bid syrup - child - 2-12yrs 5ml od or as directed

Pharmacolgy:

A comparitive study showed that iron polymaltose complex being found superior to ferrous fumarate in terms of efficacy and safety in the treatment of iron defiency anemia. Researchers observed that iron was equally bioavailable for haemoglobin synthesis from ferrous salts or iron hydroxide polymaltose at physiological and therapeutic doses. It was concluded that the advantage with iron hydroxide polymaltose complex is its wider range of safety. Iron hydroxide polymaltose therapy was hifghly effective in pregnancy related anemia. It was well tolerated and mild gastrointestinal disorders were observed in 8% of the cases which did not require any medications.

Food markedly affects bioavailability of iron in gastrointestinal lumen.

Control studies in pregnant women after the first trimester have not shown any undesirable effects on mother and neonates. It is not known how much iron from the complex is passed on into mothers milk. The administration is unlikely to cause undesirable effects to the nursed child.